Early access to new medicines

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 1, 2008, Pages 23-25

  Breckenridge, A ^a   Walley, T ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; LAPATINIB; PANITUMUMAB; PLACEBO; RALTEGRAVIR; STIRIPENTOL; SUNITINIB;

COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG QUALITY; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; LAW SUIT; LETTER; LICENSING; PATIENT SAFETY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

DRUGS, ESSENTIAL; DRUGS, INVESTIGATIONAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 45549109758     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.19     Document Type: Letter

References (8)

1. Annas, G.J. Cancer and the constitution-choice at life's end. N. Engl. J. Med. 357, 408-413 (2007).
2. Horton, R. NICE vindicated in UK's High Court. Lancet 370, 547-548 (2007).
3. Guideline on compassionate use in the European Community pursuant to Article 83 and the Annex of Regulation (EC) No 726/2004 (EMEA/27170/06). 〈http://www.emea.europa.eu/pdfs/human/euleg/2717006en.pdf〉. Accessed 5 January 2008.
4. Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council. 〈http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/ vol-1/reg_2006_507/reg_2006_507_en.pdf〉. Accessed 5 January 2008.
5. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No. 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 EMEA/509951/2006 〈http://www.emea.europa.eu/pdfs/human/regaffair/50995106en.pdf〉. Accessed 5 January 2008.
6. Cooksey, D. A review of UK health research funding HM Treasury. 〈http://www.hm-treasury.gov.uk/media/4/A/pbr06_ cooksey_final_report_636. pdf〉 (2006). Accessed 6 January 2008.
7. Krumholz, H.M., Ross, J.S., Presler, A.H. & Egilman, D.S. What have we learnt from Vioxx? BMJ 334, 120-123 (2007).
8. Suntharalingam, G et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).